Razavi Mahboubeh, Karimian Hamed, Yeong Chai Hong, Sarji Sazilah Ahmad, Chung Lip Yong, Nyamathulla Shaik, Noordin Mohamed Ibrahim
Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Department of Biomedical Imaging and University of Malaya Research Imaging Centre, Faculty of Medicine, Kuala Lumpur, Malaysia.
Drug Des Devel Ther. 2015 Jun 19;9:3125-39. doi: 10.2147/DDDT.S82935. eCollection 2015.
The purpose of this study is to evaluate the in vitro and in vivo performance of gastro-retentive matrix tablets having Metformin HCl as model drug and combination of natural polymers. A total of 16 formulations were prepared by a wet granulation method using xanthan, tamarind seed powder, tamarind kernel powder and salep as the gel-forming agents and sodium bicarbonate as a gas-forming agent. All the formulations were evaluated for compendial and non-compendial tests and in vitro study was carried out on a USP-II dissolution apparatus at a paddle speed of 50 rpm. MOX2 formulation, composed of salep and xanthan in the ratio of 4:1 with 96.9% release, was considered as the optimum formulation with more than 90% release in 12 hours and short floating lag time. In vivo study was carried out using gamma scintigraphy in New Zealand White rabbits, optimized formulation was incorporated with 10 mg of (153)Sm for labeling MOX2 formulation. The radioactive samarium oxide was used as the marker to trace transit of the tablets in the gastrointestinal tract. The in vivo data also supported retention of MOX2 formulation in the gastric region for 12 hours and were different from the control formulation without a gas and gel forming agent. It was concluded that the prepared floating gastro-retentive matrix tablets had a sustained-release effect in vitro and in vivo, gamma scintigraphy played an important role in locating the oral transit and the drug-release pattern.
本研究的目的是评估以盐酸二甲双胍为模型药物并结合天然聚合物的胃滞留型骨架片的体外和体内性能。采用湿法制粒法,以黄原胶、罗望子种子粉、罗望子核粉和白芨作为凝胶形成剂,碳酸氢钠作为气体形成剂,共制备了16种制剂。对所有制剂进行了药典和非药典测试,并在USP-II溶出装置上以50转/分钟的桨速进行了体外研究。由白芨和黄原胶按4:1比例组成、释放率为96.9%的MOX2制剂被认为是最佳制剂,在12小时内释放率超过90%且漂浮滞后时间短。在新西兰白兔中使用γ闪烁扫描术进行体内研究,将优化后的制剂与10毫克(153)Sm结合以标记MOX2制剂。放射性氧化钐用作标记物以追踪片剂在胃肠道中的转运。体内数据也支持MOX2制剂在胃区域保留12小时,且与不含气体和凝胶形成剂的对照制剂不同。得出的结论是,所制备的漂浮胃滞留型骨架片在体外和体内均具有缓释作用,γ闪烁扫描术在定位口服转运和药物释放模式方面发挥了重要作用。